A clinician's paradigm in the treatment of psoriasis - 21/08/11
New York, New York
Abstract |
Psoriasis is a chronically recurring inflammatory disease that affects the skin, scalp, and joints. It ranges in severity from mild to severe, and patients with moderate to severe disease experience significant deterioration in quality of life. The goals of psoriasis treatment are to gain initial and rapid control of the disease process, decrease the percentage of body surface area involved, decrease plaque lesions, achieve and maintain long-term remission, minimize adverse events, and improve patient quality of life. Therapy varies depending on disease severity and spread and will shift from control of acute flares to long-term maintenance. Topical treatment for mild psoriasis includes the use of topical corticosteroids, calcipotriene, tazarotene, topical tars, anthralin, and keratolytics. Treatment of moderate to severe psoriasis includes systemic therapies, such as methotrexate, acitretin, cyclosporine, and biologic agents. Treatment can be effected using combination, rotational, or sequential regimens. Treatment algorithms developed by a 2002 consensus conference are described. Because some degree of therapy will always be necessary, ranging from maintenance of long-term remission to control of acute psoriasis flares, each patient requires an individualized plan.
Le texte complet de cet article est disponible en PDF.Plan
This article is part of a supplement supported by Connetics Corp, Palo Alto, California. Disclosure: Dr Lebwohl or members of his faculty have been investigators for Abbott, Allergan, Amgen, Biogen, Centocor, Connetics, Fujisawa, Galderma, Genentech, GlaxoSmithKline, and Novartis. Dr Lebwohl has been a consultant and/or speaker for Allergan, Amgen, Biogen, Centocor, Connetics, Fujisawa, and Genentech. |
Vol 53 - N° 1S
P. S59-S69 - juillet 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?